Subarna Chakravorty, MBBS, FRCPath, MRCPCH, PhD, King’s College Hospital NHS Foundation Trust, London, UK, discusses the results of the Phase III RISE UP trial (NCT05031780) of mitapivat, a pyruvate kinase activator, in sickle cell disease, which showed a significant hemoglobin response and reduction in hemolysis, but not a statistically significant reduction in pain crises. Dr Chakravorty suggests that mitapivat may be beneficial as an adjunct to hydroxyurea treatment and notes that its mechanism of action may potentially lead to long-term improvements in organ function. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.